Table 1.
EABA in renal neoplasms
| EABA Staining Positivity (%) (CS>=10) | EABA AQUATMScore (mean CS of positive cores) | ||||
|---|---|---|---|---|---|
| Diagnosis | N | w/o EB blocker | w/ EB blocker | w/o EB blocker | w/ EB blocker |
| Benign | 31 | 77 (46/60)* | 0 (0/62) | 37.4 | |
| Onco | 30 | 93 (56/60) | 48 (29/60)* | 64.9 | 26.2 |
| chrRCC | 18 | 6 (2/36) | 0 (0/34) | 25.8 | |
| clRCC | 45 | 0 (0/87) | 0 (0/88) | ||
| pRCC | 21 | 0 (0/39) | 0 (0/39) | ||
| clRCC G/E | 19 | 33 (11/39) | 0 (0/38) | 55.6 | |
| pRCC G/E | 29 | 35 (19/55) | 10 (5/52) | 65.3 | 37.6 |
EABA, endogenous avidin binding activity; EB, endogenous biotin; RCC, renal cell carcinoma; Onco, oncocytoma; chr, chromophobe; cl, clear cell; p, papillary; G/E, granular/eosinophilic; AQUA™, automated quantitative analysis; N, number of cases; CS, composite score;
*
numbers in parentheses = positive cores over total cores evaluated in each group; w/, with; w/o, without.